AAV9 is highlighted as the leading viral vector platform for cardiac gene therapy due to its strong cardiac tropism, safety, and efficacy.
Prioritizes AAV9 for cardiac gene therapy trials in HF; extends translational potential for genetic cardiomyopathies.
Gene therapy allows for the treatment of genetic diseases by targeting the underlying molecular cause. It necessitates delivering exogenous genetic material to affected tissue to silence, replace, or activate the expression of specific genes. Currently, viral vectors are the preferred method for achieving efficient delivery of genetic material. Among them, adeno-associated viruses (AAVs) are the leading platform in gene therapy owing to their favorable safety profile, efficacy, and versatility. In particular, AAV9 exhibits the strongest cardiac tropism, making it the vector of choice for gene therapy targeting heart disease.
No takes yet. Share an insight, caveat, or question.
Bianan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: